SiBone (NASDAQ:SIBN) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Si-Bone from “Hold” to “Buy.” Analysts overall have a “Moderate Buy” consensus, with an average price target of $25.
• Si-Bone’s latest quarter beat expectations: its $0.08-per-share loss was narrower than forecast, and revenue of $55.7 million exceeded estimates.
• Insiders sold shares worth about $8 million over the past three months, including CEO Laura Francis, though insiders retained 4% of the company’s stock.

SiBone (NASDAQ:SIBN - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. TD Cowen raised their price target on shares of SiBone from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Tuesday. Truist Financial lifted their price objective on SiBone from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, October 14th. Citigroup restated a "market outperform" rating on shares of SiBone in a report on Tuesday. Needham & Company LLC decreased their price target on shares of SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Tuesday. Finally, UBS Group upped their price objective on SiBone from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $25.00.

SiBone Price Performance

NASDAQ SIBN opened at $24.24 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The business's fifty day moving average is $19.81 and its two-hundred day moving average is $16.59. SiBone has a 1 year low of $11.48 and a 1 year high of $25.92. The stock has a market capitalization of $1.08 billion, a P/E ratio of -78.19 and a beta of 0.64.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The company had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. On average, research analysts forecast that SiBone will post -0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at SiBone

In other news, insider Anshul Maheshwari sold 3,247 shares of the firm's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $25.00, for a total transaction of $81,175.00. Following the completion of the transaction, the insider directly owned 211,250 shares of the company's stock, valued at approximately $5,281,250. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Laura Francis sold 75,000 shares of the business's stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $25.30, for a total value of $1,897,500.00. Following the completion of the transaction, the chief executive officer directly owned 304,256 shares in the company, valued at approximately $7,697,676.80. This represents a 19.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 372,859 shares of company stock valued at $8,034,168 over the last three months. 4.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SiBone

Large investors have recently modified their holdings of the company. First Light Asset Management LLC lifted its holdings in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after buying an additional 2,774,795 shares during the period. Granahan Investment Management LLC boosted its stake in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock valued at $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its stake in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock valued at $14,228,000 after buying an additional 598,300 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after purchasing an additional 182,465 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of SiBone by 101.6% during the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after purchasing an additional 238,219 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

SiBone Company Profile

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.